Wall Street Analysts Are Bullish on Top Healthcare Picks

view original post

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on NovoCure (NVCRResearch Report) and Argenx Se (ARGXResearch Report) with bullish sentiments.

NovoCure (NVCR)

Wells Fargo analyst Larry Biegelsen maintained a Buy rating on NovoCure yesterday and set a price target of $49.00. The company’s shares closed last Wednesday at $14.64, close to its 52-week low of $10.87.

According to TipRanks.com, Biegelsen is a 5-star analyst with an average return of 12.2% and a 63.3% success rate. Biegelsen covers the Healthcare sector, focusing on stocks such as Axonics Modulation Technologies, GE Healthcare Technologies Inc, and Bausch + Lomb Corporation.

NovoCure has an analyst consensus of Moderate Buy, with a price target consensus of $28.60.

See today’s best-performing stocks on TipRanks >>

Argenx Se (ARGX)

Wells Fargo analyst Derek Archila maintained a Buy rating on Argenx Se yesterday and set a price target of $478.00. The company’s shares closed last Wednesday at $398.59.

According to TipRanks.com, Archila is a 4-star analyst with an average return of 8.9% and a 44.9% success rate. Archila covers the Healthcare sector, focusing on stocks such as Zentalis Pharmaceuticals, Apellis Pharmaceuticals, and Arvinas Holding Company.

Currently, the analyst consensus on Argenx Se is a Moderate Buy with an average price target of $474.09, which is a 18.8% upside from current levels. In a report issued on March 13, Morgan Stanley also maintained a Buy rating on the stock with a $515.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on NVCR: